A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO IN ADULT SUBJECTS ON BACKGROUND TOPICAL THERAPY, WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Latest Information Update: 10 Nov 2023
At a glance
- Drugs Abrocitinib (Primary) ; Dupilumab
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms JADE Compare
- Sponsors Pfizer
- 01 Oct 2023 Results of pooled analysis from JADE MONO-1 (NCT03349060), JADE MONO-2 (NCT03575871) and JADE COMPARE (NCT03720470) and JADE EXTEND assessing patient-reported outcomes with long-term abrocitinib treatment in patients with moderate-to-severe AD published in the Journal of the European Academy of Dermatology and Venereology
- 01 Oct 2023 Results from three phase 3 studies( JADE MONO1 (NCT03349060), JADE MONO2 (NCT03575871) and JADE COMPARE (NCT03720470)), including the long term extension JADE EXTEND study(Data cut-off: April 22, 2020) evaluating efficacy of abrocitinib and long term safety in patients with moderate to severe AD, published in the Journal of the European Academy of Dermatology and Venereology.
- 22 May 2023 Results of a post hoc analysis assessing the efficacy and safety of abrocitinib and dupilumab in a subset of patients with severe and/or difficult-to-treat atopic dermatitis, published in the American Journal of Clinical Dermatology.